Bright Minds Biosciences Inc. (DRUG) saw a significant price increase of 49.98% in pre-market trading, reaching a 52-week high. This surge follows the announcement of promising results from the Phase 2 trial of BMB-101, which demonstrated a 73.1% median reduction in absence seizures among patients with drug-resistant epilepsy. The positive trial results indicate strong efficacy and safety, which has generated considerable investor interest.
The stock's movement is attributed to the confirmed positive results from the Phase 2 BREAKTHROUGH trial for BMB-101, which is aimed at treating drug-resistant absence seizures. The trial's success highlights the drug's potential in addressing a critical medical need, further enhancing market confidence in Bright Minds' future prospects. This announcement has led to a surge in investor anticipation, contributing to the stock's impressive performance.
The implications of these results are significant for Bright Minds Biosciences, as they not only validate the company's research and development efforts but also position BMB-101 as a potential market leader in treating epilepsy. The upcoming conference call to discuss these results is expected to further engage investors and bolster the company's market presence.
Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 121.00 USD with a low forecast of 80.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 121.00 USD with a low forecast of 80.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 80.240
Low
80.00
Averages
121.00
High
147.00
Current: 80.240
Low
80.00
Averages
121.00
High
147.00
Baird
NULL -> Outperform
upgrade
$82 -> $142
2026-01-07
Reason
Baird
Price Target
$82 -> $142
AI Analysis
2026-01-07
upgrade
NULL -> Outperform
Reason
Baird raised the firm's price target on Bright Minds to $142 from $82 and keeps an Outperform rating on the shares. The firm updated its model following the release of data from its BMB-101 trial data which showed an absence of seizures.
BTIG
NULL -> Buy
upgrade
$72 -> $147
2026-01-07
Reason
BTIG
Price Target
$72 -> $147
2026-01-07
upgrade
NULL -> Buy
Reason
BTIG raised the firm's price target on Bright Minds to $147 from $72 and keeps a Buy rating on the shares. The first readout for BMB-101 in absence seizures was very strong, showing a 73% reduction in a heavily pre-treated cohort, highlighting its potential as a salvage therapy in a large market with few well-tolerated options, the analyst tells investors in a research note. While efficacy appears impressive across lines, further evaluation of safety and data in earlier treatment lines will be key, as the company plans pivotal trials for both absence seizures and Developmental and Epileptic Encephalopathies, with promising implications for Prader-Willi Syndrome given the drug's targeted mechanism, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DRUG
Unlock Now
Baird
NULL -> Outperform
maintain
$75 -> $82
2025-11-07
Reason
Baird
Price Target
$75 -> $82
2025-11-07
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Bright Minds to $82 from $75 and keeps an Outperform rating on the shares. The firm updated its model as the BMB-105 Pader-Willi program holds promise.
BTIG
initiated
$72
2025-09-08
Reason
BTIG
Price Target
$72
2025-09-08
initiated
Reason
BTIG initiated coverage of Bright Minds with a Buy rating and $72 price target. The company is developing a \"very specific\" 5-HT2C agonist, BMB-101, for epilepsies that has better dosing than bexicaserin, the analyst tells investors in a research note. The firm believes the dosing advantage is relevant given data suggesting the side effects of the 5-HT2C class may be peak concentration-dependent. The relatively high percentage of absence seizures in otherwise healthy children suggests convenient dosing and low side effects \"are a major positive,\" contends BTIG. It expects Phase 2 data from Bright Minds around year-end 2025.
About DRUG
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
